Citations for
1JAK2, PRV
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian JJ, McMullin MF, Ruggeri M, Besses C, Vannucchi AM, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann CA, Pietra D, Pascutto C, Haferlach T, Cazzola M.
Blood 117(10):2813-6. Epub 2011 Jan 11. 2011
2JAK2, MPD, MPL, PRV
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Kilpivaara O, Levine RL.
Leukemia 22(10):1813-7. Epub 2008 Aug 28. Review. 2008
3JAK2, MPD, PML, PRV
Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A.
Am J Hematol 83(6):491-7. Review. 2008
4JAK2, MPD, PRV
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR.
N Engl J Med 356(5):459-68. 2007
5PRV, JAK2
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, Yallop D, Arya R, Pagliuca A, Gken J, Wendon J, Heaton ND, Mufti GJ.
Gastroenterology 130(7):2031-8. 2006
6PRV
The polycythaemia rubra vera-1 gene is constitutively expressed by bone marrow cells and does not discriminate polycythaemia vera from reactive and other chronic myeloproliferative disorders.
Bock O, Serinsoz E, Neusch M, Schlue J, Kreipe H.
Br J Haematol 123(3):472-4. 2003